{"id":967518,"date":"2026-05-27T09:31:25","date_gmt":"2026-05-27T13:31:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/phr-deadline-alert-levi-korsinsky-reminds-phreesia-inc-phr-investors-of-securities-class-action-deadline-on-july-13-2026\/"},"modified":"2026-05-27T09:31:25","modified_gmt":"2026-05-27T13:31:25","slug":"phr-deadline-alert-levi-korsinsky-reminds-phreesia-inc-phr-investors-of-securities-class-action-deadline-on-july-13-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/phr-deadline-alert-levi-korsinsky-reminds-phreesia-inc-phr-investors-of-securities-class-action-deadline-on-july-13-2026\/","title":{"rendered":"PHR Deadline Alert: Levi & Korsinsky Reminds Phreesia, Inc. (PHR) Investors of Securities Class Action Deadline on July 13, 2026"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Alert: Phreesia’s March 30 Corrective Disclosure Wiped Out $3.03 Per Share in Value as Concealed Pharmaceutical Marketing Weakness Reached the Market<\/i>\n <\/p>\n

\n NEW YORK<\/span>, May 27, 2026<\/span> \/PRNewswire\/ — Levi &\u00a0Korsinsky, LLP notifies investors in Phreesia, Inc. (NYSE: PHR) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between May 8, 2025 and March 30, 2026. Find out if you qualify to recover losses<\/a>. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com<\/a>\u00a0or (212) 363-7500.<\/p>\n

\n

\n
\n \"Levi
\n <\/a>\n <\/p>\n<\/p><\/div>\n

PHR shares fell 27% in a single session, declining $3.03 per share from $11.41 to $8.38, after Phreesia slashed its fiscal 2027 revenue outlook by as much as $39 million. To be considered for lead plaintiff, investors must file by July 13, 2026.<\/p>\n

\n The March 30 After-Hours Revelation<\/b>\n <\/p>\n

After the market closed on March 30, 2026, Phreesia disclosed that pharmaceutical manufacturers were committing lower spend levels for the second half of fiscal 2027 than anticipated. The Company cut its revenue guidance from a range of $545 million to $559 million down to $510 million to $520 million, citing “worsening visibility” and weakened commitments in its Network Solutions segment.<\/p>\n

The lawsuit contends that this information was not new to management. Throughout the Class Period, executives allegedly<\/span><\/span> assured investors that visibility into future revenue was consistent with prior years, even as pharmaceutical clients were pulling back commitments.<\/p>\n

\n How the Market Repriced PHR Shares<\/b>\n <\/p>\n

The corrective disclosure triggered an immediate repricing of Phreesia stock as the market absorbed information that had allegedly<\/span><\/span> been withheld:<\/p>\n